Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 心不全における射出分子のスペクトル全体におけるサクビトリル/バルサタン
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 心不全における射出分子のスペクトル全体におけるサクビトリル/バルサタン

関連する実験動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K

心不全における射出分子のスペクトル全体におけるサクビトリル/バルサタン

Scott D Solomon1, Muthiah Vaduganathan1, Brian L Claggett1

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).

Circulation
|November 19, 2019

PubMed で要約を見る

まとめ
この要約は機械生成です。

サクビトリル/ バルサタンは,エジェクション分数の範囲で心臓不全の患者に恩恵を与え,特に入院を減らす. 心不全の女性は,男性よりも高いエジェクション分数から利益を得ました.

科学分野:

  • 心臓病科
  • 薬理学について

背景:

  • 保存されたエジェクション分数 (HFpEF) による心不全 (HF) に対して,限られた疾患修正療法が存在する.
  • サクビトリル/ バルサータンの有効性は,左心室エジェクション分数 (LVEF) の全スペクトルにおいて,依然として研究対象である.

研究 の 目的:

  • レニン・アニオテンシン・アルドステロン系 (RAAS) 阻害剤と比較して,LVEFスペクトルにおけるサクビトリル/バルサタンの効果を評価する.
  • LVEFに関連して心血管疾患による死亡と心不全による入院の治療効果を分析する.

主な方法:

  • PARADIGM-HF (LVEF ≤40%) と PARAGON-HF (LVEF ≥45%) 試験のプール分析
  • 分析のためにLVEFグループ (≤22. 5%から> 62. 5%) に分類された患者.
  • 心血管疾患による死亡までの時間,HF入院,死亡率の評価

主要な成果:

  • サクビトリル/ バルサータンは,心血管疾患による死亡とHF入院のRAAS抑制に優れていることが示されました.
  • 治療効果はLVEFによって変化し,幅広い範囲で,特に正常なLVEF以下で利益が観察されました.
  • 女性は男性より高いLVEFの範囲に及ぶ治療効果を経験しました.
キーワード:
臨床効果心不全サクビトリル/バルサタン室内射出分数

さらに関連する動画

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.9K

関連する実験動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.9K

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

857
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
857
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

184
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
184
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

757
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
757
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

710
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
710
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

633
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
633
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

結論:

  • サクビトリル/ バルサタンは,心不全の治療効果を様々な LVEF にわたって提供し,特に軽く減少したエジェクション分数に及ぶ.
  • 特にHF入院の利点は,女性ではより高いLVEF範囲まで観察されています.